

RECEIVED  
CENTRAL FAX CENTER

MAR 14 2007

**FAX TRANSMISSION****DATE:** March 14, 2007**PTO IDENTIFIER:** Application Number 09/602740 – Conf. No. 1632  
Patent Number**Inventor:** Markus Pompejus et al.**MESSAGE TO:** US Patent and Trademark Office**FAX NUMBER:** (571) 273-8300**FROM:** LAHIVE & COCKFIELD, LLP  
Maria Laccotripe Zacharakis, Ph.D., J.D.**PHONE:** (617) 227-7400**Attorney Dkt. #:** BGI-126CP**PAGES (Including Cover Sheet):** 7**CONTENTS:** Request for Acknowledgement of Previously Submitted Information Disclosure Statement (2 pages)  
Certificate of Transmission (1 page)  
Appendix A (3 pages)

If your receipt of this transmission is in error, please notify this firm immediately by collect call to sender at (617) 227-7400 and send the original transmission to us by return mail at the address below.

This transmission is intended for the sole use of the individual and entity to whom it is addressed, and may contain information that is privileged, confidential and exempt from disclosure under applicable law. You are hereby notified that any dissemination, distribution or duplication of this transmission by someone other than the intended addressee or its designated agent is strictly prohibited.

LAHIVE & COCKFIELD, LLP  
28 State Street, Boston, Massachusetts 02109  
Telephone: (617) 227-7400 Facsimile: (617) 742-4214

MAR 14 2007

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted by facsimile to the Patent and Trademark Office, facsimile no. (571) 273-8300 at Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: March 14, 2007

Signature:

(Maria Lacortina Zacharakis, Ph.D., J.D.)

Docket No.: BGI-126CP  
(PATENT)**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Markus Pompejus *et al.*

Application No.: 09/602740

Group Art Unit: 1652

Filed: June 23, 2000

Examiner: C. L. Fronda

For: Polynucleotides Encoding A 6-  
Phosphogluconolactonase Polypeptide From  
*Corynebacterium Glutamicum*

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**REQUEST FOR ACKNOWLEDGEMENT OF PREVIOUSLY SUBMITTED  
INFORMATION DISCLOSURE STATEMENT (IDS)**

Dear Sir:

During a routine review of the file associated with the payment of the Issue Fee for the above-identified application, Applicants noticed that PTO Form SB/08, submitted with the Information Disclosure Statement (IDS) filed on November 29, 2006 in the above-identified application, has not yet been initialed by the Examiner and returned to Applicants.

As evidenced by Appendix A, submitted herewith, the IDS and its accompanying documents (PTO Form SB/08 and Transmittal Letter) were filed on November 29, 2006. These documents were received by the U.S. Patent and Trademark Office, as indicated by the U.S. Patent Application Information Retrieval database.

Moreover, as indicated on the IDS filed on November 29, 2006 and pursuant to 37 CFR 1.97(e)(1), all references listed on the PTO Form SB/08 filed on November 29, 2006 were first

MAR 14 2007

Application No.: 09/602740

Docket No.: BGI-126CP

cited in a communication from a foreign patent office in a counterpart Canadian application not more than three months prior to the filing of the Information Disclosure Statement.

Therefore, Applicants respectfully request that the Examiner initial the PTO Form SB/08 originally submitted on November 29, 2006 (a copy of which is enclosed herewith - 1 page), and return a copy of the initialed form to Applicants to signify that the aforementioned references have been considered and made of record in the present application.

If there are any remaining issues, the Examiner is invited to call the undersigned at (617) 227-7400.

Dated: March 14, 2007

Respectfully submitted,

By 

Maria Laccotripe Zacharakis, Ph.D., J.D.

Registration No.: 56,266

LAHIVE &amp; COCKFIELD, LLP

One Post Office Square

Boston, Massachusetts 02109

(617) 227-7400

Attorney/Agent For Applicants

I hereby certify that this paper (as with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: November 29, 2006 Signature: \_\_\_\_\_

(Maria Lacootripe Zacharskie, Ph.D., J.D.)

Docket No.: BGI-126CP  
(PATENT)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:  
Markus Pompejus *et al.*RECEIVED  
CENTRAL FAX CENTER

MAR 14 2007

Application No.: 09/602,740

Confirmation No.: 1632

Filed: June 23, 2000

Art Unit: 1652

For: CORYNEBACTERIUM GLUTAMICUM  
GENES ENCODING PROTEINS INVOLVED  
IN CARBON METABOLISM AND ENERGY  
PRODUCTION

Examiner: C. L. Fronda

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (SIDS)

Dear Sir:

In accordance with 37 CFR 1.97, Applicants hereby make of record the following additional documents. A PTO Form SB/08 and a full copy of each of the documents required under 37 CFR 1.98(a)(2) accompany this statement.

Applicants have become aware of the following documents, cited in a Canadian Office Action issued October 2, 2006, during the prosecution of Canadian Application No. 2,383,875, which corresponds to the above-referenced application, and in accordance with 37 CFR 1.97(d) and (e)(1), hereby submit these documents for the Examiner's consideration. These documents are cited on the enclosed PTO Form SB/08, and a copy of each document required under 37 CFR 1.98(a)(2) is also enclosed.

I hereby certify, pursuant to 37 CFR 1.97(e)(1), that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign

MAR 14 2007

Application No.: 09/602,740

Docket No.: BGI-126CP

patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

Accordingly, although this Information Disclosure Statement is filed after the mailing date of a Final Office Action but before payment of the Issue Fee (37 CFR 1.97(d)), Applicants hereby petition that the Information Disclosure Statement be considered in accordance with 37 C.F.R. 1.97(d).

This statement is not to be interpreted as a representation that the cited documents are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any document herein be construed *per se* as a representation that such document is prior art. Moreover, Applicants understand the Examiner will make an independent evaluation of the cited documents.

Please charge our Deposit Account No. 12-0080 in the amount of \$180.00 covering the fee set forth in 37 CFR 1.17(p). The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 12-0080, under Order No. BGI-126CP.

Dated: November 29, 2006

MLZ/MG/mch

Respectfully submitted,

By 

Maria Laccotripe Zacharakis, Ph.D., J.D.

Registration No.: 56,266

LAHIVE &amp; COCKFIELD, LLP

One Post Office Square

Boston, Massachusetts 02109-2127

(617) 227-7400

(617) 742-4214 (Fax)

Attorney/Agent For Applicants

MAR 14 2007

PTO/SB/08a/b (07-06)

Approved for use through 09/30/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>		<b>Complete If Known</b>			
		Application Number	09/602,740-Conf. #1632		
		Filing Date	June 23, 2000		
		First Named Inventor	Markus POMPEJUS		
		Art Unit	1652		
		Examiner Name	C. L. Fronda		
Sheet	1	of	1	Attorney Docket Number	BGI-126CP

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 601.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C1	Broun, Pierre et al., "Catalytic Plasticity of Fatty Acid Modification Enzymes Underlying Chemical Diversity of Plant Lipids," <i>Science</i> , Vol. 282:1315-1317 (1998)	
	C2	Ng, David H.W. et al., "Point Mutation In the Second Phosphatase Domain of CD45 Abrogates Tyrosine Phosphatase Activity," <i>Biochemical and Biophysical Research Communications</i> , Vol. 206(1):302-309 (1995)	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

MAR 14 2007

PTO/SB/97 (09-04)

Approved for use through 07/31/2009. OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.


Application No. (if known): 09/802740

Attorney Docket No.: BGI-126CP

**Certificate of Transmission under 37 CFR 1.8**

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office.

on March 14, 2007  
Date



Signature

Maria Laccotripe Zacharakis, Ph.D., J.D.

Typed or printed name of person signing Certificate

56.266

Registration Number, if applicable

(617) 227-7400

Telephone Number

Note: Each paper must have its own certificate of transmission, or this certificate must identify each submitted paper.

Request for Acknowledgement of Previously Submitted Information

Disclosure Statement (2 pages)

Appendix A (3 pages)

This Certificate of Transmission (1 page)